S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:EIGR

Eiger BioPharmaceuticals Competitors

$9.24
-0.77 (-7.69 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.18
Now: $9.24
$10.00
50-Day Range
$9.61
MA: $10.89
$12.30
52-Week Range
$4.55
Now: $9.24
$13.99
Volume336,876 shs
Average Volume296,820 shs
Market Capitalization$300.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54

Competitors

Eiger BioPharmaceuticals (NASDAQ:EIGR) Vs. CHRS, MESO, CRTX, ADVM, INBX, and AERI

Should you be buying EIGR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Eiger BioPharmaceuticals, including Coherus BioSciences (CHRS), Mesoblast (MESO), Cortexyme (CRTX), Adverum Biotechnologies (ADVM), Inhibrx (INBX), and Aerie Pharmaceuticals (AERI).

Eiger BioPharmaceuticals (NASDAQ:EIGR) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Eiger BioPharmaceuticals and Coherus BioSciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-3.00
Coherus BioSciences$356.07 million3.12$89.83 million$1.2312.39

Coherus BioSciences has higher revenue and earnings than Eiger BioPharmaceuticals. Eiger BioPharmaceuticals is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eiger BioPharmaceuticals and Coherus BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eiger BioPharmaceuticalsN/A-100.60%-57.76%
Coherus BioSciences33.06%90.98%27.33%

Volatility & Risk

Eiger BioPharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Eiger BioPharmaceuticals and Coherus BioSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eiger BioPharmaceuticals00203.00
Coherus BioSciences01502.83

Eiger BioPharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 170.56%. Coherus BioSciences has a consensus target price of $27.8571, indicating a potential upside of 82.73%. Given Eiger BioPharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eiger BioPharmaceuticals is more favorable than Coherus BioSciences.

Insider & Institutional Ownership

68.8% of Eiger BioPharmaceuticals shares are owned by institutional investors. 5.8% of Eiger BioPharmaceuticals shares are owned by company insiders. Comparatively, 15.9% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Coherus BioSciences beats Eiger BioPharmaceuticals on 10 of the 13 factors compared between the two stocks.

Eiger BioPharmaceuticals (NASDAQ:EIGR) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Eiger BioPharmaceuticals and Mesoblast's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-3.00
Mesoblast$32.16 million33.54$-77,940,000.00($0.74)-12.41

Eiger BioPharmaceuticals has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Eiger BioPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eiger BioPharmaceuticals and Mesoblast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eiger BioPharmaceuticalsN/A-100.60%-57.76%
Mesoblast-591.00%-18.69%-13.85%

Volatility & Risk

Eiger BioPharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.71, meaning that its share price is 271% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Eiger BioPharmaceuticals and Mesoblast, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eiger BioPharmaceuticals00203.00
Mesoblast13202.17

Eiger BioPharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 170.56%. Mesoblast has a consensus target price of $14.55, indicating a potential upside of 58.50%. Given Eiger BioPharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eiger BioPharmaceuticals is more favorable than Mesoblast.

Insider & Institutional Ownership

68.8% of Eiger BioPharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Mesoblast shares are owned by institutional investors. 5.8% of Eiger BioPharmaceuticals shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eiger BioPharmaceuticals (NASDAQ:EIGR) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Eiger BioPharmaceuticals and Cortexyme, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eiger BioPharmaceuticals00203.00
Cortexyme21402.29

Eiger BioPharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 170.56%. Cortexyme has a consensus target price of $50.00, indicating a potential upside of 37.48%. Given Eiger BioPharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eiger BioPharmaceuticals is more favorable than Cortexyme.

Volatility & Risk

Eiger BioPharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Eiger BioPharmaceuticals and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eiger BioPharmaceuticalsN/A-100.60%-57.76%
CortexymeN/A-37.78%-35.24%

Valuation & Earnings

This table compares Eiger BioPharmaceuticals and Cortexyme's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-3.00
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75

Cortexyme is trading at a lower price-to-earnings ratio than Eiger BioPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

68.8% of Eiger BioPharmaceuticals shares are owned by institutional investors. Comparatively, 55.5% of Cortexyme shares are owned by institutional investors. 5.8% of Eiger BioPharmaceuticals shares are owned by company insiders. Comparatively, 19.8% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cortexyme beats Eiger BioPharmaceuticals on 6 of the 11 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Risk & Volatility

Adverum Biotechnologies has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Adverum Biotechnologies and Eiger BioPharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
Eiger BioPharmaceuticals00203.00

Adverum Biotechnologies presently has a consensus price target of $23.50, indicating a potential upside of 114.42%. Eiger BioPharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 170.56%. Given Eiger BioPharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eiger BioPharmaceuticals is more favorable than Adverum Biotechnologies.

Profitability

This table compares Adverum Biotechnologies and Eiger BioPharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Eiger BioPharmaceuticalsN/A-100.60%-57.76%

Earnings and Valuation

This table compares Adverum Biotechnologies and Eiger BioPharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-3.00

Adverum Biotechnologies has higher revenue and earnings than Eiger BioPharmaceuticals. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Eiger BioPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 68.8% of Eiger BioPharmaceuticals shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by insiders. Comparatively, 5.8% of Eiger BioPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Adverum Biotechnologies beats Eiger BioPharmaceuticals on 9 of the 12 factors compared between the two stocks.

Eiger BioPharmaceuticals (NASDAQ:EIGR) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Eiger BioPharmaceuticals and Inhibrx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eiger BioPharmaceuticals00203.00
Inhibrx00403.00

Eiger BioPharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 170.56%. Inhibrx has a consensus target price of $34.6667, indicating a potential upside of 30.52%. Given Eiger BioPharmaceuticals' higher probable upside, analysts plainly believe Eiger BioPharmaceuticals is more favorable than Inhibrx.

Profitability

This table compares Eiger BioPharmaceuticals and Inhibrx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eiger BioPharmaceuticalsN/A-100.60%-57.76%
InhibrxN/AN/AN/A

Earnings & Valuation

This table compares Eiger BioPharmaceuticals and Inhibrx's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-3.00
InhibrxN/AN/AN/AN/AN/A

Institutional and Insider Ownership

68.8% of Eiger BioPharmaceuticals shares are owned by institutional investors. Comparatively, 36.6% of Inhibrx shares are owned by institutional investors. 5.8% of Eiger BioPharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eiger BioPharmaceuticals (NASDAQ:EIGR) and Aerie Pharmaceuticals (NASDAQ:AERI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Eiger BioPharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Aerie Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Eiger BioPharmaceuticals and Aerie Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eiger BioPharmaceuticals00203.00
Aerie Pharmaceuticals11902.73

Eiger BioPharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 170.56%. Aerie Pharmaceuticals has a consensus target price of $25.50, indicating a potential upside of 32.47%. Given Eiger BioPharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eiger BioPharmaceuticals is more favorable than Aerie Pharmaceuticals.

Profitability

This table compares Eiger BioPharmaceuticals and Aerie Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eiger BioPharmaceuticalsN/A-100.60%-57.76%
Aerie Pharmaceuticals-231.05%-135.57%-37.23%

Earnings & Valuation

This table compares Eiger BioPharmaceuticals and Aerie Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-3.00
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66

Eiger BioPharmaceuticals has higher earnings, but lower revenue than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than Eiger BioPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

68.8% of Eiger BioPharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Aerie Pharmaceuticals shares are owned by institutional investors. 5.8% of Eiger BioPharmaceuticals shares are owned by insiders. Comparatively, 9.7% of Aerie Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Eiger BioPharmaceuticals beats Aerie Pharmaceuticals on 8 of the 13 factors compared between the two stocks.


Eiger BioPharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.